Kidney Week 2020 Reimagined: Call for Late-Breaking Clinical Trials
ASN will accept Late-Breaking Clinical Trial (LBCT) submissions electronically from July 15, 2020 through September 2, 2020 (2:00 p.m. ET). Submissions should discuss randomized trials (Phase II & III) that will have significant impact on clinical practice. ASN requires ASN User Logins and current DISCLOSURES FOR ALL AUTHORS at time of submission.
Table of Contents
- General Guidelines
- Submission Information
- Assignment, Notification & Presentation
- Confidential Advanced Access
Clinical trials "are designed to add to medical knowledge related to the treatment, diagnosis, and prevention of diseases or conditions. Some common reasons for conducting clinical studies include: Evaluating one or more interventions…for treating a disease, syndrome, or condition…Finding ways to prevent the initial development or recurrence of a disease or condition…Evaluating one or more interventions aimed at identifying or diagnosing a particular disease or condition…Examining methods for identifying a condition or risk factors for that condition…Exploring and measuring ways to improve the comfort and quality of life of people with a chronic illness through supportive care" (ClinicalTrials.gov).
Your LBCT submission must meet the following criteria for ASN consideration:
- ASN considers submissions for Phase II and III trials only.
- Your data has not been and will not be presented at a U.S. or international meeting before presentation at Kidney Week.
- Your data has not been and will not be published in any form (including preprint servers) before presentation at Kidney Week.
- The lead author (i.e., individual submitting the LBCT and presenting the LBCT if accepted) has the authority to submit the LBCT and transfer copyright on behalf of the co-authors and company sponsors.
- All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.
- Submit as much data as possible. The late-breaking clinical trials committee will make their decisions and assignments based on the information submitted.
- Do not submit multiple abstracts on the same trials - only one abstract submission per trial.
- All abstracts must be submitted electronically through the ASN abstract submission site by September 2, 2020, 2:00 p.m. ET for consideration.
- Lead Author: A lead author must be assigned for each abstract submission.
- This individual is the first author listed in the submission and has the primary responsibility for communications with ASN.
- This individual must have an ASN User Login with current contact information for submission.
- This individual must have a current financial and other relationship disclosure affidavit on file with ASN. (Click here for the ASN Conflict of Interest and Disclosure Policy.)
- This individual is responsible for ensuring that all co-authors and company sponsors approve the submission, publication, and potential presentation.
- This individual will give the oral or poster presentation if the submission is accepted. The lead author should feel comfortable presenting and answering questions in English.
- Co-Authors: Each co-author must have an ASN User Login with current contact information and must have a current financial and other relationship disclosure affidavit on file with ASN. The co-authors will be listed in the order provided during submission.
- Authors and Contributors: With regard to authorship credit, ASN has adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the current update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: "Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3."
Note the full text of the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals. In addition, with regard to contributors, ASN has adopted the following statement of editorial policy from the Information for Authors of the Annals of Internal Medicine: "Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts (Daskalopoulou, Jacobs). These writers should be acknowledged on the byline or in the Acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The editors consider failure to acknowledge these contributors ghostwriting, which is contrary to Annals' editorial policy."
- An abstract submission may contain a maximum of 2,500 characters, and the count includes characters and spaces in the following: Authors Names, Title, Body, Figure, and Table. Figure count is determined by image height but will not exceed 560 characters. Table count is 50 characters per row. Please note that Author Institutions do not count towards the character count.
- The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. If the lead author does not receive an email confirmation within two business days of submission, please email firstname.lastname@example.org immediately. Lack of email confirmation indicates that ASN did not receive the submission.
- There is no limit to the number of abstracts that an individual may submit. However, there is a $85 nonrefundable processing fee per submission. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
- Upon abstract submission, the lead author and co-authors agree to all copyright transfer terms and the ASN embargo policy.
- Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers.
- Changes: It is important that the lead author checks the abstract data carefully before submission. For submitted abstracts needing minimal changes through September 2, 2020, the contact author can make changes directly in the abstract submission site. After September 2, please email email@example.com for change requests which will be handled on a case-by-case basis; ASN may not be able to accommodate all requests.
- Withdrawals: The lead author can request abstract withdrawal through September 30, 2020 by emailing firstname.lastname@example.org. Please note the abstract number in the email subject line and the lead author's name in the email body. The $85 processing fee is nonrefundable. After September 30, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.
Assignment, Notification & Presentation
All abstract submissions are peer reviewed by the LBCT subcommittee, and authors' names and institutions are blinded to reviewers. LBCT submissions can be (1) accepted as an oral abstract, (2) accepted as a poster, or (3) rejected. There is no publication-only option for LBCT submissions.
Accepted abstracts will be assigned to one of the following:
- High-Impact Clinical Trials Oral Session: Each abstract presentation will be followed by audience questions, facilitated by the session moderator(s). Abstracts accepted for this session will be included in the ASN Abstract Supplement PDF, which will be posted online by October 25, 2020.
- Late-Breaking Posters: If accepted for poster presentation, the lead author or a co-author must be available at the poster board from 10:00 a.m. to 12:00 p.m. for presentation and discussion. Abstracts accepted for poster presentations will be included in the ASN Abstract Supplement PDF, which will be posted online by October 25, 2020.
It is the responsibility of the lead authors to share the notifications with their co-authors. If you are a lead author and have not received your notification by October 1, please email email@example.com and note the abstract number in the email subject line and the lead author's name in the email body.
The presenting authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply).
ASN reserves the right to withdraw any submission for any reason in its discretion.
Confidential Advanced Access
All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.